Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
FRAMINGHAM, MA / ACCESSWIRE / January 14, 2021 /Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced today that Jeffrey Eisenberg, Chief Executive Officer of Xenetic will present at NobleCon17 - Noble Capital Markets' Seventeenth Annual Investor Conference on Tuesday, January 19, 2021 at 9:45 AM ET.
FRAMINGHAM, MA / ACCESSWIRE / January 5, 2021 / Xenetic Biosciences, Inc.
FRAMINGHAM, MA / ACCESSWIRE / December 14, 2020 / Xenetic Biosciences, Inc.
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 9) * AbbVie Inc (NYSE: ABBV) (announced positive results of a late-stage study of upadacitinib in ulcerative colitis) * Acceleron Pharma Inc (NASDAQ: XLRN) * Aerpio Pharmaceuticals Inc (NASDAQ: ARPO) * Apellis Pharmaceuticals Inc (NASDAQ: APLS) * Avanos Medical Inc (NYSE: AVNS) * Bioanalytical Systems, Inc. (NASDAQ: BASI) * BioCryst Pharmaceuticals,...
FRAMINGHAM, MA / ACCESSWIRE / December 10, 2020 / Xenetic Biosciences, Inc.
Shares of Xenetic Biosciences Inc. skyrocketed on massive volume toward a 17-month high in morning trading Wednesday, after the Massachusetts-based biopharmaceutical company said its partner PJSC Pharmsynthez provided "positive" data from a Phase 3 trial of its treatment for anemia patients with kidney disease. The stock blasted 349.4% higher on volume of 140.3 million shares, which was enough to make it the most actively traded on major U.S. exchanges, and compared with the full-day average of...
(NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, today announced its partner, PJSC Pharmsynthez, has reported in a press release positive data from its pivotal Phase 3 clinical study leveraging PolyXen® to develop a treatment for anemia in patients with chronic kidney disease (CKD).